Literature DB >> 28328183

Seroprevalence of Bartonella species, Coxiella burnetii and Toxoplasma gondii among patients with hematological malignancies: A pilot study in Romania.

C J Messinger1, E S Gurzau2,3, E B Breitschwerdt4,5, C I Tomuleasa6,7, S J Trufan8, M M Flonta9, R G Maggi4,5, I Berindan-Neagoe6,10,11, P M Rabinowitz8.   

Abstract

Patients receiving immunosuppressive cancer treatments in settings where there is a high degree of human-animal interaction may be at increased risk for opportunistic zoonotic infections or reactivation of latent infections. We sought to determine the seroprevalence of selected zoonotic pathogens among patients diagnosed with haematologic malignancies and undergoing chemotherapeutic treatments in Romania, where much of the general population lives and/or works in contact with livestock. A convenience sample of 51 patients with haematologic cancer undergoing chemotherapy at a referral clinic in Cluj-Napoca, Romania, was surveyed regarding animal exposures. Blood samples were obtained and tested for evidence of infection with Bartonella species, Coxiella burnetii and Toxoplasma gondii, which are important opportunistic zoonotic agents in immunocompromised individuals. 58.8% of participants reported living or working on a farm, and living or working on a farm was associated with contact with livestock and other animals. 37.5% of participants were IgG seroreactive against one or more of five Bartonella antigens, and seroreactivity was statistically associated with living on farms. Farm dwellers were 3.6 times more likely to test IgG seroreactive to Bartonella antibodies than non-farm dwellers. 47.1% of the participants tested T. gondii IgG positive and 13.7% tested C. burnetii IgG positive, indicating past or latent infection. C. burnetii IgM antibodies were detected in four participants (7.8%), indicating possible recent infection. These results indicate that a large proportion of patients with haematologic cancer in Romania may be at risk for zoonotic infections or for reactivation of latent zoonotic infections, particularly with respect to Bartonella species. Special attention should be paid to cancer patients' exposure to livestock and companion animals in areas where much of the population lives in rural settings.
© 2017 Blackwell Verlag GmbH.

Entities:  

Keywords:  zzm321990Bartonellazzm321990; zzm321990Coxiella burnetiizzm321990; zzm321990Toxoplasmazzm321990; immunocompromised patients; livestock; seroprevalence; zoonoses

Mesh:

Year:  2017        PMID: 28328183     DOI: 10.1111/zph.12353

Source DB:  PubMed          Journal:  Zoonoses Public Health        ISSN: 1863-1959            Impact factor:   2.702


  4 in total

1.  The seroprevalence of Bartonella spp. in the blood of patients with musculoskeletal complaints and blood donors, Poland: a pilot study.

Authors:  Monika E Łysakowska; Olga Brzezińska; Małgorzata Szybka; Magdalena Konieczka; Sylwia Moskwa; Małgorzata Brauncajs; Joanna Makowska; Dorota Pastuszak-Lewandoska; Janina Grzegorczyk
Journal:  Clin Rheumatol       Date:  2019-05-22       Impact factor: 2.980

2.  Molecular survey of neglected bacterial pathogens reveals an abundant diversity of species and genotypes in ticks collected from animal hosts across Romania.

Authors:  Martin O Andersson; Conny Tolf; Paula Tamba; Mircea Stefanache; Gabriel Radbea; Dimitrios Frangoulidis; Herbert Tomaso; Jonas Waldenström; Gerhard Dobler; Lidia Chitimia-Dobler
Journal:  Parasit Vectors       Date:  2018-03-20       Impact factor: 3.876

3.  Seroprevalence and risk factors of Toxoplasma gondii infection in oral cancer patients in China: a case-control prospective study.

Authors:  N Zhou; X Y Zhang; Y X Li; L Wang; L L Wang; W Cong
Journal:  Epidemiol Infect       Date:  2018-07-13       Impact factor: 4.434

4.  Castleman's disease in the HIV-endemic setting.

Authors:  Esam-Rajab Mahroug; Candice Sher-Locketz; Minodora-Silvia Desmirean; Emmanuel-Akinola Abayomi; Ciprian Tomuleasa; Ravnit Grewal
Journal:  Cancer Manag Res       Date:  2018-10-12       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.